Amanote Research
Register
Sign In
Prostate Cancer Responds to Anti–PD-1–ctla4 Combo
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2019-039
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
March 20, 2019
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients
JCI insight
Medicine
Early Evidence of Anti-Pd-1 Activity in Enzalutamide-Resistant Prostate Cancer
Oncotarget
Oncology
Anti-Caveolin-1 Antibodies as Anti-Prostate Cancer Therapeutics
Hybridoma
PD-L1 Upregulation Drives Escape From Anti-Ctla4 and Radiation Therapy
Cancer Discovery
Oncology
The Efficacy and Safety of Anti-Pd-1/Pd-L1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First-Line Treatment for Advanced Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
Erratum: The Efficacy and Safety of Anti‐PD‐1/Pd‐l1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First‐line Treatment for Advanced Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
Atezolizumab Combo Approved for PD-L1–positive TNBC
Cancer Discovery
Oncology
Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Clinical Cancer Research
Cancer Research
Oncology
Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment
International Journal of Clinical Oncology
Medicine
Surgery
Oncology
Hematology
